Let's Talk About INAVO120
From Let's Talk About SACT by BOPA, British oncology pharmacy association
August 3, 2025 · 32 min · Episode 42
About this episode
The episode discusses the Inavo120 study and its implications for breast cancer treatment.
In this episode we are joined by Suzanne Frank. We discuss Inavo120 (Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer) study. We discuss the relevance of the data and how it might change practice going forward. This study is available to read at https://www.nejm.org/doi/full/10.1056/NEJMoa2404625 and the update at https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.1003
People in this episode
Guest: Suzanne Frank
Topics covered
- breast cancer
- PIK3CA mutation
- oncology
- clinical study
- medical practice
Keywords
- Inavo120
- Inavolisib
- breast cancer
- PIK3CA
- oncology
- clinical research
- medical practice
Mentioned in this episode
Organizations: BOPA, NEJM, ASCO
Products: Inavo120
More episodes of Let's Talk About SACT
- Let's Talk About Melanoma Focus · March 3, 2026 · 23 min
- Let's Talk About Menopause and Cancer · January 14, 2026 · 24 min
- Let's Talk About The Immunotherapy Specialist Advisory Group · December 1, 2025 · 33 min
- Let's Talk About The Cancer Research UK Consent Form Project · November 13, 2025 · 25 min
- Let's Talk About The Duffy Null Variant · October 12, 2025 · 45 min
- Let's Talk About Online Misinformation · September 14, 2025 · 20 min
Explore listener stats, chart rankings, contacts and more on the Let's Talk About SACT podcast page.